Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes

Ralph A. DeFronzo

doi:10.2337/dc11-0064

Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes

Ralph A. DeFronzo

Research output: Contribution to journal › Review article › peer-review

199 Scopus citations

Abstract

Both as monotherapy and in combination with other OHAs, timed bromocriptine (Cycloset) causes a 0.6-0.7%reduction in HbA_1c and reduces plasma triglyceride and FFA concentrations in type 2 diabetic patients. In a 52-week safety study, Cycloset decreased the cardiovascular composite end point by 40%. Other advantages of Cycloset include absence of hypoglycemia since insulin secretion is not stimulated, weight neutrality, no need for dose adjustment in patients with moderate renal insufficiency, lack of edema and CHF, and good side effect profile.

Original language	English (US)
Pages (from-to)	789-794
Number of pages	6
Journal	Diabetes care
Volume	34
Issue number	4
DOIs	https://doi.org/10.2337/dc11-0064
State	Published - Apr 2011

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialized Nursing

Access to Document

10.2337/dc11-0064

Cite this

@article{bb207e50f0e047d288d0aebb6eec28f3,

title = "Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes",

abstract = "Both as monotherapy and in combination with other OHAs, timed bromocriptine (Cycloset) causes a 0.6-0.7%reduction in HbA1c and reduces plasma triglyceride and FFA concentrations in type 2 diabetic patients. In a 52-week safety study, Cycloset decreased the cardiovascular composite end point by 40%. Other advantages of Cycloset include absence of hypoglycemia since insulin secretion is not stimulated, weight neutrality, no need for dose adjustment in patients with moderate renal insufficiency, lack of edema and CHF, and good side effect profile.",

author = "DeFronzo, {Ralph A.}",

year = "2011",

month = apr,

doi = "10.2337/dc11-0064",

language = "English (US)",

volume = "34",

pages = "789--794",

journal = "Diabetes care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "4",

}

TY - JOUR

T1 - Bromocriptine

T2 - A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes

AU - DeFronzo, Ralph A.

PY - 2011/4

Y1 - 2011/4

N2 - Both as monotherapy and in combination with other OHAs, timed bromocriptine (Cycloset) causes a 0.6-0.7%reduction in HbA1c and reduces plasma triglyceride and FFA concentrations in type 2 diabetic patients. In a 52-week safety study, Cycloset decreased the cardiovascular composite end point by 40%. Other advantages of Cycloset include absence of hypoglycemia since insulin secretion is not stimulated, weight neutrality, no need for dose adjustment in patients with moderate renal insufficiency, lack of edema and CHF, and good side effect profile.

AB - Both as monotherapy and in combination with other OHAs, timed bromocriptine (Cycloset) causes a 0.6-0.7%reduction in HbA1c and reduces plasma triglyceride and FFA concentrations in type 2 diabetic patients. In a 52-week safety study, Cycloset decreased the cardiovascular composite end point by 40%. Other advantages of Cycloset include absence of hypoglycemia since insulin secretion is not stimulated, weight neutrality, no need for dose adjustment in patients with moderate renal insufficiency, lack of edema and CHF, and good side effect profile.

UR - http://www.scopus.com/inward/record.url?scp=79956188611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956188611&partnerID=8YFLogxK

U2 - 10.2337/dc11-0064

DO - 10.2337/dc11-0064

M3 - Review article

C2 - 21447659

AN - SCOPUS:79956188611

SN - 0149-5992

VL - 34

SP - 789

EP - 794

JO - Diabetes care

JF - Diabetes care

IS - 4

ER -

Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this